SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092914
Filing Date
2024-08-07
Accepted
2024-08-07 16:45:23
Documents
65
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20240630.htm   iXBRL 10-Q 2075487
2 EX-10.1 avir-ex10_1.htm EX-10.1 29496
3 EX-31.1 avir-ex31_1.htm EX-31.1 14178
4 EX-31.2 avir-ex31_2.htm EX-31.2 14393
5 EX-32.1 avir-ex32_1.htm EX-32.1 9740
6 EX-32.2 avir-ex32_2.htm EX-32.2 9099
  Complete submission text file 0000950170-24-092914.txt   7206120

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT avir-20240630.xsd EX-101.SCH 923394
67 EXTRACTED XBRL INSTANCE DOCUMENT avir-20240630_htm.xml XML 1094729
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 241184534
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)